Drugs / Tedisamil
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT00126022 | Dec 2004 → Mar 2006 | atrial fibrillation, atrial flutter | Solvay Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT00126074 | Oct 2004 → Mar 2006 | atrial fibrillation, atrial flutter | Solvay Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT00126061 | Oct 2004 → Jan 2006 | atrial fibrillation, atrial flutter | Solvay Pharmaceuticals | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Tedisamil | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00126022 ↗ |
| Known as | KC-8857 | ChEMBL registry synonym — accepted as the source's own label CHEMBL113461 ↗ |
| Modality | Small molecule | — CHEMBL113461 ↗ |
| Route | Intravenous | “Intravenous Tedisamil” NCT00126022 ↗ |